Truveta
Truveta pools daily EHR data from 30 US health systems for research and AI tools.
Truveta's hospital data pipeline is hard to copy, but Epic Cosmos already sits inside the same hospitals and the revenue-to-cash-raised gap is wide.
Truveta combines medical records from 130 million patients across 800+ hospitals owned by 30 health systems, then uses AI to help researchers and companies search and understand that data. Copying this is difficult because Truveta's owners are the hospitals themselves (they trust each other and share governance), and big competitors like IQVIA and Optum face conflicts of interest or lack that same trust arrangement; new AI models cannot simply grab hospital records without permission. The biggest question is whether Epic Cosmos, a competing product from Epic Systems, can build something similar or better, and whether Truveta's member hospitals stay loyal or leave for other deals.
A founding or major member health system (e.g. Providence, Trinity Health) exits or does not renew data contribution. Would show the co-ownership governance model is fracturing and data supply is at risk.
Truveta discloses revenue below roughly $50M against its $500M+ raised. Would show the business is burning capital far faster than it is converting data access into paying customers.
- 130M+ patients from 800+ hospitals
- $320M Series C, Jan 2025, led by Trinity Health
- Revenue estimated $64M-$80M vs $500-620M raised
- Unclear revenue against $500-620M raised leaves profitability path unproven.
- Member health-system defection could undermine exclusive data pipeline moat.
- Ongoing privacy and antitrust scrutiny of multi-health-system data monetization since 2021.
- Epic Cosmos could emerge as a structurally credible, EHR-native competitive threat.
| Rival | Direction | Evidence |
|---|---|---|
| TriNetX | contesting | TriNetX claims ~250-300M patients across a federated global network vs Truveta's 130M US-focused dataset, 2026 |
| Epic Cosmos | contesting | Structurally positioned EHR-native rival but no confirmed marquee account win from Truveta as of 2026-07 |
| IQVIA | gaining on | Truveta's provider-owned model bypasses IQVIA's broker-based sourcing, appealing directly to health systems, 2025-2026 |
| Optum | gaining on | Optum's payer ownership under UnitedHealthcare creates a conflict of interest Truveta's health-system-owned structure avoids |
- Is Truveta profitable in 2026?
- Truveta has not disclosed profitability. It raised a $320M Series C on January 13, 2025, led by Trinity Health with Regeneron, Illumina and Providence, signaling it remains in growth and reinvestment mode rather than confirmed profitability as of mid 2026.
- Who owns Truveta?
- Truveta is owned and governed by its member health systems, not a VC-majority cap table. Founded September 2020 by Providence, Advocate Health, Tenet Healthcare and Trinity Health, it grew from 14 founding members in Feb 2021 to 30 health-system owners by 2025.
- Could AI replace Truveta?
- No. Truveta's value is an exclusive, daily-refreshed EHR data pipeline from 30 owner health systems covering 130M+ patients across 800+ hospitals, not the algorithm layer. Its April 28, 2026 Truveta Intelligence tool uses AI to query that proprietary data, not to replace it.
- Is Truveta laying off employees?
- No layoffs have been reported. Truveta has instead been hiring, adding Dr. Johnathan Lancaster as President and Chief Scientific Officer on January 26, 2026 and Providence CEO Erik Wexler to its board on March 31, 2026, alongside senior roles across science and product.
- Who is Truveta's biggest competitor?
- TriNetX is Truveta's closest rival, claiming roughly 250 to 300 million patients across a federated global EHR network as of 2026, versus Truveta's 130 million US-focused, daily-refreshed dataset. Epic Cosmos is a structurally positioned but unproven emerging threat.
- Does Truveta have real pharma customers or just pilots?
- Truveta names paying life-sciences customers including Pfizer (first customer, 2022), Regeneron (customer since January 2023, later an investor), Illumina, Boston Scientific and Dexcom, plus peer-reviewed research using its data published in JAMA and JACC: Heart Failure between 2023 and 2026.
- 2026-05-12Announced collaboration with Knit Health to train its Large Clinical Behavior Model on Truveta Data
- 2026-04-28Launched Truveta Intelligence, AI natural-language query tool over 130M-patient dataset
- 2026-03-31Added Providence CEO Erik Wexler to Truveta's board
- 2026-01-27Launched real-time clinical trials solution for trial design and site selection
- 2026-01-26Hired ex-Regeneron SVP Dr. Johnathan Lancaster as President and Chief Scientific Officer
- 2026-01-13Announced $320M Series C led by Trinity Health; launched Truveta Live Link
- 2021-07Closed Series A of approximately $95M led by Trinity Health
- 2020-09Founded by Providence, Advocate Health, Tenet Healthcare and Trinity Health
- Truveta - Headcount, Funding & Open Jobs (2026-07-03)
- Truveta 2026 Company Profile
- Truveta lands $320M to fuel creation of massive new genome project (2025-01-13)
- Truveta Inc. Asset Profile (2025-01-12)
- Truveta Stock for Accredited Investors (2026-07-07)
- Truveta unveils Truveta Intelligence (2026-04-28)
- Tech Moves | Truveta hires President and Chief Scientific Officer (2026-01-27)
- Truveta Names Providence CEO Erik Wexler to Board (2026-03-31)
- Truveta launches Truveta Live Link (2026-01-13)
- Truveta launches real-time clinical trials solution (2026-01-27)
- Truveta and Knit Health collaborate on clinical AI (2026-05-12)
- TriNetX Dataworks-USA review (2026-04-21)